STATEMENT OF NEED

Lung cancer remains the leading cause of cancer-related deaths, with an estimated 226,650 new cases diagnosed and 124,730 deaths in the United Stated in 2025 (Siegel et al, 2025). Non–small cell lung cancer (NSCLC) is a biologically heterogenous type of lung cancer associated with a range of molecular alterations, including human epidermal growth factor 2 (HER2) mutations in approximately 4% of cases. HER2 represents a promising therapeutic target, with National Comprehensive Cancer Network (NCCN) 2026 guidelines now recommending testing for rare oncogenic driver alterations, including HER2 mutations, to personalize therapeutic decision making. While biomarker testing is critical to improving outcomes for patients with NSCLC, challenges such as cost, time, access, and awareness pose barriers to its implementation, particularly in the community setting where resources may be limited (Salazar et al, 2025; Ismail et al, 2025). Multidisciplinary collaboration between oncologists, pathologists, nurses, and other members of the care team is crucial to streamline biomarker testing, select the optimal treatment for individual patients, and manage treatment-related toxicities. In this Virtual Tumor Board, Tejas Patil, MD, Assistant Professor of Thoracic Oncology and Associate Director of Clinical Affairs at the University of Colorado Cancer Center; Beth Sandy, MSN, CRNP, FAPO, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of the University of Pennsylvania; and Maureen F. Zakowski, MD, JD, Thoracic Pathologist and Chief of the Cytopathology Service at Mount Sinai Medical Center, will explore the application of advances and best practices in HER2-mutant NSCLC in the community setting.  

TARGET AUDIENCE

Community oncologists, pathologists, oncology nurses, advanced practice providers, pharmacists, and other healthcare professionals (HCPs) involved in the care of patients with non–small cell lung cancer (NSCLC).

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

• Apply evidence-based algorithms for selecting and sequencing therapies in HER2-mutant NSCLC
• Develop monitoring and management protocols for interstitial lung disease and other common toxicities associated with HER2-targeted therapies
• Implement practical strategies for overcoming barriers to timely molecular testing in community oncology practice

REGISTRATION

JOINTLY ACCREDITED PROVIDER

In support of improving patient care, i3 Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

i3 Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

By providing this information, participants are agreeing to allow i3 Health to share this information with the ACCME.

Physician Assistants/Associates

i3 Health has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until 12/17/26. PAs should only claim credit commensurate with the extent of their participation.

Nurse Practitioners

The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Nursing Continuing Professional Development 

A maximum of 1.0 ANCC contact hour may be earned by learners who successfully complete this nursing continuing professional development activity. This activity has been designated for 0.6 contact hours of pharmacology credit for Advanced Practice Registered Nurses.

Provider approved by the California Board of Registered Nursing, Provider Number 15824, for 1.0 ANCC contact hour. 

ONCC RECERTIFICATION

The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.

OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1.0 ILNA point toward:

• Care Continuum (OCN®, CBCN®, CPHON®, AOCNP®)
• Nursing Practice (CBCN®)
• Oncology Nursing Practice (OCN®)

as well as:

OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 0.3 ILNA points toward:

• Diagnosis and Staging (CBCN®)
• Symptom Management, Palliative Care, Supportive Care (OCN®, CPHON®, AOCNP®)

Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course.

Continuing Pharmacy Education

i3 Health has approved this knowledge-based activity for 1.0 ACPE CE hour. The Universal Activity Number for this activity is JA0008128-0000-25-037-H01-P. Pharmacy CE credits can be submitted to the NABP upon successful completion of the activity and the evaluation by providing your NABP ID and DOB, which must be submitted within 60 days of completion. 

DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH INELIGIBLE COMPANIES

i3 Health endorses the standards of the ACCME, ANCC, and ACPE that require everyone in a position to control the content of a CME/NCPD/CPE activity to disclose all financial relationships with ineligible companies that are related to the content of the CME/NCPD/CPE activity. CME/NCPD/CPE activities must be balanced, independent of commercial bias, and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.

A conflict of interest is created when an individual has an opportunity to affect CME/NCPD/CPE content about products or services of an ineligible company with which he/she has a financial relationship, which therefore may bias their opinions and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks, or other financial benefits.

i3 Health will identify, review, and mitigate all relevant financial relationships that speakers, authors, or planners disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. i3 Health does not endorse any products or services.

Relevant financial relationships exist between the following individuals and ineligible companies:

Tejas Patil, MD, discloses that he has served on an advisory board or panel for AADI Bioscience, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Caris, Cellworks, Daiichi Sankyo, Foundation Medicine, Galvanize, Guardant Health, Gilead, Guidepoint, Johnson & Johnson, Jazz Pharmaceuticals, Merus, Natera, Nuvation, Pfizer, Regeneron, Rigel, Roche/Genentech, Summit Therapeutics, and Takeda; that he has served as a consultant for Boehringer Ingelheim and Johnson & Johnson; and that he has received grants/research support from Gilead and Johnson & Johnson. 

Beth Sandy, MSN, CRNP, FAPO, discloses that she has served on an advisory board or panel for Pfizer; that she has served on a speaker's bureau for Amgen, AstraZeneca, Janssen, Jazz, Lilly, and Merck; and that she has served as a consultant for Catalyst.

Maureen F. Zakowski, MD, JD, has no relevant financial relationships to disclose. 

The i3 Health planners, reviewers, and managers have nothing to disclose.

i3 Health has mitigated all relevant financial relationships.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, participants must watch the video and submit a completed evaluation at the end of the activity.

TECHNOLOGY REQUIREMENTS FOR VIRTUAL CME | NCPD | CPE ACTIVITIES

For virtual (asynchronous, archived live, home study; synchronous webinars) CME/NCPD/CPE activities, include access to system requirements:

• The Internet browser(s) supported and minimum versions of each required by the learner to complete the online activity.
• The minimum memory, storage, processor, and Internet speeds require by the learner to complete the online activity.

UNAPPROVED USE DISCLOSURE

i3 Health requires CME/NCPD/CPE faculty (speakers) to disclose to attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved), as well as any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling.

This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

DISCLAIMER

The information provided at this CME/NCPD/CPE activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

COMMERCIAL SUPPORT

This activity is supported by an independent medical education grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Aggregate participant data will be shared with commercial supporters of this activity.

CONTACT INFORMATION

Technical queries or questions regarding activity credit should be directed to i3 Health at support@i3health.com.